Vemurafenib and BRAF inhibition: A new class of treatment for metastatic melanoma Journal Article


Authors: Luke, J. J.; Hodi, F. S.
Article Title: Vemurafenib and BRAF inhibition: A new class of treatment for metastatic melanoma
Abstract: The U.S. Food and Drug Administration recently approved vemurafenib for the treatment of BRAF valine in exon 15, at codon 600 (V600E) mutant metastatic melanoma. Vemurafenib is a competitive small-molecule serine-threonine kinase inhibitor that functions by binding to the ATP-binding domain of mutant BRAF. Compared with dacarbazine chemotherapy, vemurafenib significantly improved the 6-month overall survival of patients from 64% to 84% and exhibited a response rate of approximately 50%. Median progression-free survival was also significantly improved with vemurafenib as compared with dacarbazine (5.3 versus 1.6 months, respectively), and this was consistent among groups analyzed, including age, sex, geography, Eastern Cooperative Oncology Group status, disease stage, and serum lactate dehydrogenase. The success of targeting melanoma genomics has created a paradigm shift for future drug development. Currently, the elucidation of resistant mechanisms to vemurafenib therapy remains an important area of active investigation that will shape rational drug treatments for melanoma. The development of vemurafenib, the role of BRAF targeting, and the changing landscape of treatment for melanoma provide a new foundation for clinical investigation. ©2011 AACR.
Keywords: cancer survival; treatment response; overall survival; mutation; drug tolerability; fatigue; review; squamous cell carcinoma; drug dose reduction; drug efficacy; liver function; nonhuman; recommended drug dose; side effect; treatment duration; drug approval; drug targeting; animals; dacarbazine; ipilimumab; melanoma; quality of life; drug eruption; enzyme inhibition; arthralgia; drug dose escalation; pruritus; sulfonamides; skin papilloma; drug dose increase; indoles; alopecia; b raf kinase; photosensitivity; proto-oncogene proteins b-raf; keratoacanthoma; clinical trial (topic); vemurafenib
Journal Title: Clinical Cancer Research
Volume: 18
Issue: 1
ISSN: 1078-0432
Publisher: American Association for Cancer Research  
Date Published: 2012-01-01
Start Page: 9
End Page: 14
Language: English
DOI: 10.1158/1078-0432.ccr-11-2197
PROVIDER: scopus
PUBMED: 22083257
DOI/URL:
Notes: --- - "Export Date: 1 March 2012" - "CODEN: CCREF" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Jason Luke
    12 Luke